Obesity is a medical condition, sometimes considered a disease, in which excess body fat has accumulated to such an extent that it can potentially have negative effects on health. People are classified as obese when their body mass index (BMI)—a person's weight divided by the square of the person's height—is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight.
Obesity is a major cause of disability and is correlated with various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, certain types of cancer, and osteoarthritis.
Obesity is associated with the impairment of normal GH (growth hormone), GLP-1 secretion, and responses to all stimuli such as GH-releasing hormone (GHRH), hypoglycaemia, L-dopa, arginine, glucagon, physical exercise, and sleep.
Glucagon-like peptide-1 (GLP-1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion.
NA-931: the first Triple Action of three major hormones receptors/agonists of IGF-1, GLP-1 and GIP
Press release Biomed Industries, Inc. Announces the First Triple IGF-1/GLP-1/GIP Receptor Agonist NA-931 for the Treatment of Obesity
NA-931™ regulates the homeostasis of insulin-like growth factor (IGF-1) function, GLP-1 and GIP associated with diabetes obesity.
NA-931 can easily cross the blood brain barrier, so only a small dose of the drug is required to be effective. The drug shows the following properties:
* NA-931™ exhibits neuroprotection
* NA-931 regulates IGF-1, GLP-1 and GIP
* It has great bioavailability in the body
* It is very safe, with no toxicity observed
* It has been shown to significantly reduce the body mass index, without causing muscle loss
* It is available in oral formulation: convenient for patient to take one capsule once a day.
NA-931 is in Phase 2B clinical trials. NA-931 not only significantly reduces body fat but also preserves muscle mass. Furthermore, NA-931 exhibits a notable reduction in adverse events commonly associated with existing treatments.
In the triple action mechanism of NA-931, Insulin-like Growth Factor 1 (IGF-1) plays a pivotal role in fuel metabolism and regulation of body composition. Additionally, GIP and GLP‐1 have been shown to be effective for weight loss in non-diabetic patients with obesity when given as adjunctive therapy to diet and exercise. IGF-1 also contributes to modulating glucagon secretion by inhibiting the ability of low glucose concentration to stimulate glucagon expression and secretion.
The Phase 3 clinical trials of NA-931 have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.
View a selected list of PUBLICATIONS and PRESENTATIONS at CONFERENCES
For further information about our products, please contact us. Contact us